Why Isn’t the Scale Moving? Slow Progress, Plateaus, Hunger, and Losing Too Fast on a GLP-1

Slow progress on a GLP-1 usually comes down to your dose, how long you've been on it, how consistently you take it, which medication you use, or personal factors.

For context, people in clinical trials lost about 15% of their body weight on average with semaglutide 2.4 mg and about 21% with tirzepatide. Losing less than 5% after 3 months, or more than 5% in a single month, is worth discussing with your prescriber (1, 2).

Why am I not losing weight?

• Give it time at the right dose. Judge your results after 3 months at the highest dose you can tolerate, not while your dose is still being raised. If you've lost 5% or more, staying on treatment makes sense. If you've lost less, your prescriber will review how consistently you take it and your dose, and may consider switching medications, such as from semaglutide to tirzepatide (1, 2).
• Switching isn't a guaranteed fix. People who never responded well to semaglutide may also respond less to tirzepatide than people who responded and then plateaued (2).
• Real life is different from clinical trials. Results in everyday practice are lower. On semaglutide, people lost about 8% at 60 weeks if they had diabetes and about 11% if they didn't (3).
• Some personal factors are linked to smaller losses. These include type 2 diabetes, insulin resistance, being male, older age, missed doses, and eating and activity habits (4, 5). Some studies also link higher starting weight or blood sugar (HbA1c) to smaller losses. However, a 2026 analysis found no difference in effect by starting BMI or HbA1c (6).
• Missed doses and breaks add up. Each extra month of treatment is linked to more weight loss (4, 5).

How much should I lose each week?

• About 0.5 to 2 lb (0.23 to 0.91 kg) per week is the usual safe range (1).
• Expect it to slow down. Most weight comes off in the first 6 months. Loss then slows and levels off around 18 months (3).
• Watch the trend, not the daily number. Your weight naturally bounces around from week to week. Monthly changes, or your percentage lost over time, tell you much more (3).

Why have I plateaued?

• Everyone plateaus. It happens when the medication reaches its full effect and your body adapts to weight loss. Your body burns fewer calories and sends stronger hunger signals (3, 7, 8).
• Habits can drift. In everyday life, plateaus also come from missing doses or slipping back into old eating and activity patterns over time (9).
• A plateau is the maintenance phase, not a failure. With continued treatment, weight stays down for at least 4 years (3). Stopping the medication leads to regaining about 7% to 12% of body weight within a year (7).
• If you start regaining, talk to your prescriber. Regaining more than 5% is a reason to discuss restarting or raising your dose (7).

Why am I still hungry or experiencing "food noise"?

• How the medication curbs appetite: GLP-1 medications act mainly on the brain's hunger, fullness and reward centers (10, 11).
• The effect varies from person to person. Genetics, including differences in the gene for the GLP-1 receptor, may play a role (5).
• Common reasons hunger persists (8):
  • Your dose is still too low, or it is still being raised.
  • The effect wears off near the end of the week, before your next injection.
  • Your body pushes back against weight loss over time.
  • Your meals are low in protein and fiber.
• Set realistic expectations. These medications reduce hunger, cravings and the pull toward high-fat foods. They don't stop eating for pleasure in everyone. Research specifically on "food noise" is still limited (12).

Knowledge is only half the battle

Knowing what to do is not the same as getting it done

A stall can come from a dozen different causes, and the fix depends on which one applies to you. Guessing wastes weeks. Sorting it out takes someone who can look at your whole picture.

This guide gives you the best evidence available, but research describes averages, and you are not an average. As a physician, I have worked with hundreds of people on GLP-1s. I combine the highest quality evidence with that experience and with your specific situation, preferences, and goals to build a plan that works for you, then adjust it as you go.

Book a free 30-minute callHow coaching works

Am I losing too fast?

• More than 5% of your body weight in one month should be checked by your prescriber. Losing that fast, or losing 14% or more over 3 to 4 months, is also a reason to pay attention to bone health (1, 2).
• There is no official cutoff for losing too much. Warning signs are fast, large losses, or weight loss that makes it harder to get through your day (1).
• What your prescriber may check: whether you are eating too little, vomiting, or becoming malnourished, and any changes in mood. They may refer you to a dietitian or lower your dose (1).

Am I losing fat or muscle?

Mostly fat, but some lean tissue too.

• Some lean-tissue loss is normal. About 25% to 39% of the weight lost on GLP-1 medications is lean tissue (13). Only part of that is actual muscle (15).
• Fat is still most of what you lose. That includes visceral fat, the deep belly fat around your organs that is most linked to health problems (9, 14).

How to keep track:

• Waist size: your waist should shrink along with your weight (1).
• Strength and function: time yourself standing up from a chair 5 times, or measure grip strength with a handheld gauge (1).
• Body composition: a DXA scan is the practical standard. Smart scales that estimate body composition are easier to get but less accurate (15).

How to protect your muscle:

• If your strength or function declines, aim for at least 1.3 grams of protein per kilogram of body weight per day, and strength train at least 2 days a week (1).
• Experts have proposed protein targets ranging from 0.8 to 1.6 grams per kilogram per day, or 80 to 120 grams a day (16).
• Adults 65 and older, and people with both obesity and low muscle mass, are at highest risk of muscle loss (1, 16).

For more detail, see my guide Protecting Your Muscle on a GLP-1.

This guide is for education only. Talk with your prescriber before changing your medication, diet or exercise plan.

Want more guides like this?

Subscribe for free and get new GLP-1 guides, free tools, and practical tips from Dr. Mahiar Rabie by email. No spam.

And if you want help applying this to your own situation, that is what I do every day with my clients.

Subscribe freeWork with me 1:1

More in the GLP-1 guide series

• How to Eat on a GLP-1
• Managing GLP-1 Side Effects
• Protecting Your Muscle on a GLP-1
• Is My GLP-1 Working?
• Keeping the Weight Off

References

1. Kushner RF, Almandoz JP, Rubino DM. Managing adverse effects of incretin-based medications for obesity. JAMA. 2025.
2. Moiz A, Peters TM, Tsoukas MA, et al. Balancing the benefits and risks of GLP-1 receptor agonists: a clinical guide for shared decision-making. EClinicalMedicine. 2026.
3. Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society. The American Journal of Clinical Nutrition. 2025.
4. Wong HJ, Sim B, Teo YH, et al. Efficacy of GLP-1 receptor agonists on weight loss, BMI, and waist circumference for patients with obesity or overweight: a systematic review, meta-analysis, and meta-regression of 47 randomized controlled trials. Diabetes Care. 2025.
5. Gaskin PS, Chami PS. Low weight loss response to incretin analogs: a systematic review. Obesity Reviews. 2026.
6. Alexander GC, Xiao X, Dilek S, et al. Heterogeneity of treatment effects of glucagon-like peptide-1 receptor agonists for weight loss in adults: a systematic review and meta-analysis. JAMA Internal Medicine. 2026.
7. Mehrtash F, Dushay J, Manson JE. Integrating diet and physical activity when prescribing GLP-1s—lifestyle factors remain crucial. JAMA Internal Medicine. 2025.
8. Damhof MA, van Bruggen FH, van Roon EN. Early weight regain after GLP-1 receptor agonist discontinuation: mechanisms and implications for treatment de-escalation strategies. Diabetes, Obesity & Metabolism. 2026.
9. Sawicka-Gutaj N, Gruszczyński D, Nijakowski K, et al. GLP-1 agonists and changes in body mass and composition in adults with overweight or obesity with or without type 2 diabetes mellitus: a systematic review and meta-analysis. International Journal of Obesity. 2026.
10. Giannakogeorgou A, Roden M. Role of lifestyle and glucagon-like peptide-1 receptor agonists for weight loss in obesity, type 2 diabetes and steatotic liver diseases. Alimentary Pharmacology & Therapeutics. 2024.
11. Holst JJ. Treatment of type 2 diabetes and obesity on the basis of the incretin system: the 2021 Banting Medal for Scientific Achievement Award Lecture. Diabetes. 2021.
12. Bettadapura S, Dowling K, Jablon K, Al-Humadi AW, le Roux CW. Changes in food preferences and ingestive behaviors after glucagon-like peptide-1 analog treatment: techniques and opportunities. International Journal of Obesity. 2025.
13. Lieberman DE, Aslan DH, Heymsfield SB. The conundrum of exercise for weight management in the GLP-1 receptor agonist era. JAMA. 2026.
14. Bhandarkar A, Bhat S, Kapoor N. Effect of GLP-1 receptor agonists on body composition. Current Opinion in Endocrinology, Diabetes, and Obesity. 2025.
15. Sukurica E, Sengul GF, Uysal Cinar F. Weight loss or muscle loss? Cellular mechanisms and clinical strategies for preserving lean mass during GLP-1-based therapy. Diabetes, Obesity & Metabolism. 2026.
16. Spreckley M, Ruggiero CF, Brown A. Bridging the nutrition guidance gap for GLP-1 receptor agonist therapy assisted weight loss: lessons from bariatric surgery. International Journal of Obesity. 2026.